Alterity Therapeutics stock rises after positive MSA trial data presented at conference

Investing.com -- Alterity Therapeutics Ltd (NASDAQ:ATHE) stock rose 3.3% in premarket trading Thursday following the company’s presentation of positive data from its Phase 2 clinical trial for Multiple System Atrophy (MSA) at a major medical conference.

The biotechnology company showcased results from its ATH434-201 randomized, double-blind trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders in Honolulu. The data demonstrated ATH434’s potential as a disease-modifying treatment for MSA, showing a slowing of disease progression and stabilization of orthostatic hypotension, one of the most challenging symptoms of the condition.

Key findings included a clinically significant reduction in disease severity relative to placebo on the modified UMSARS I activities of daily living scale, with a 48% relative treatment effect at the 50 mg dose (p=0.02) and a 30% relative treatment effect at the 75 mg dose at 52 weeks.

"The aggregate data from our double-blind trial continue to demonstrate the potential of ATH434 as a disease modifying therapy for MSA," said David Stamler, M.D., Chief Executive Officer of Alterity.

New analyses presented at the conference showed that when accounting for baseline differences in orthostatic hypotension, the efficacy signal at the 75 mg dose strengthened to a 35% relative treatment effect on the key clinical endpoint.

Additional efficacy assessments showed improvements consistent with the primary findings, including positive results on the Clinical Global Impression of Severity Scale and increased physical activity as measured by wearable movement sensors.

The company also presented data on neuroimaging biomarkers showing that ATH434 reduced iron accumulation in key brain regions compared to placebo, demonstrating target engagement. The drug was well tolerated with adverse event rates similar to placebo.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.